{"id":943,"date":"2024-01-30T23:34:24","date_gmt":"2024-01-30T23:34:24","guid":{"rendered":"https:\/\/www.eye-connect.org\/namd\/?page_id=943"},"modified":"2026-06-10T15:20:28","modified_gmt":"2026-06-10T19:20:28","slug":"home2-2","status":"publish","type":"page","link":"https:\/\/www.eye-connect.org\/namd\/","title":{"rendered":"nAMD"},"content":{"rendered":"<section class=\"l-section wpb_row height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_middle type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:1rem;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\">\n\t\t\t\t<p class=\"rs-p-wp-fix\"><\/p>\n\t\t\t\t<sr7-module data-alias=\"namd-slider-3\" data-id=\"3\" id=\"SR7_3_1\" class=\"rs-ov-hidden\" data-version=\"6.7.57\">\n\t\t\t\t\t<sr7-adjuster><\/sr7-adjuster>\n\t\t\t\t\t<sr7-content>\n\t\t\t\t\t\t<sr7-slide id=\"SR7_3_1-5\" data-key=\"5\">\n\t\t\t\t\t\t\t<sr7-txt id=\"SR7_3_1-5-2\" class=\"sr7-layer\">New Anti-VEGF Therapies for Neovascular Age-related <br \/>\nMacular Degeneration<\/sr7-txt>\n\t\t\t\t\t\t<\/sr7-slide>\n\t\t\t\t\t\t<sr7-slide id=\"SR7_3_1-6\" data-key=\"6\">\n\t\t\t\t\t\t<\/sr7-slide>\n\t\t\t\t\t<\/sr7-content>\n\t\t\t\t\t<image_lists style=\"display:none\">\n\t\t\t\t\t\t<img data-src=\"\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2024\/01\/retina-mosaic-header03.png\" data-libid=\"980\" data-lib=\"medialibrary\" title=\"retina-mosaic-header03\" width=\"0\" height=\"0\" data-dbsrc=\"Ly93d3cuZXllLWNvbm5lY3Qub3JnL25hbWQvd3AtY29udGVudC91cGxvYWRzLzIwMjQvMDEvcmV0aW5hLW1vc2FpYy1oZWFkZXIwMy5wbmc=\"\/>\n\t\t\t\t\t<\/image_lists>\n\t\t\t\t<\/sr7-module>\n\t\t\t\t<script>\n\t\t\t\t\twindow.SR7 ??={};SR7.PMH ??={}; SR7.PMH[\"SR7_3_1\"] = {cn:100,state:false,fn: function() { if (window._tpt!==undefined && window._tpt.prepareModuleHeight !== undefined) {  _tpt.prepareModuleHeight({id:\"SR7_3_1\",el:[450,450,300,275,250],type:'standard',shdw:'0',gh:[450,450,300,275,250],gw:[1240,1240,1024,778,480],vpt:['-200px&#039;,&#039;-200px&#039;,&#039;-200px&#039;,&#039;-200px&#039;,&#039;-200px'],size:{fullWidth:true, fullHeight:false},mh:'0',onh:0,onw:0,bg:{color:'{\"orig\":\"transparent\",\"type\":\"solid\",\"string\":\"transparent\"}'}});   SR7.PMH[\"SR7_3_1\"].state=true;} else if(SR7.PMH[\"SR7_3_1\"].cn-->0)\tsetTimeout( SR7.PMH[\"SR7_3_1\"].fn,19);}};SR7.PMH[\"SR7_3_1\" ].fn();\n\t\t\t\t<\/script>\n<div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><p style=\"text-align: center; font-size: 22px;\">This American Academy of Ophthalmology collection of activities provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD).<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_middle type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_medium\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row us_custom_308d0844 hide_on_tablets height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:25px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_small\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"font-size: 24px; color: #332463;\">Featured Activities<\/div>\n<\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row namd-grid-4-2-1 via_grid cols_4 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\" aria-label=\"A1416-1-thumbnail-ver2\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\" target=\"_blank\" rel=\"noopener\"><u>Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-3\/\" aria-label=\"A1416-3-thumbnail\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Switching IVT Anti-VEGF Agents for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-3\/\" target=\"_blank\" rel=\"noopener\"><u>Switching IVT Anti-VEGF Agents for nAMD: So Many Options, How to Choose?<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-3\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-4\/\" aria-label=\"A1416-4-thumbnail\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-4\/\" target=\"_blank\" rel=\"noopener\"><u>When and How to Prioritize Injection Burden for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-4\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-5\/\" aria-label=\"A1416-5-thumbnail\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Managing Retinal Fluid in Wet AMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-5\/\" target=\"_blank\" rel=\"noopener\"><u>The Human Side of nAMD: Balancing Vision, Life, and Treatment<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-5\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_4 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-2\/\" aria-label=\"A1416-2-thumbnail-ver2\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Getting Into the Details About Managing nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-2\/\" target=\"_blank\" rel=\"noopener\"><u>Did You Know? Getting Into the Details About Managing nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-2\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\" aria-label=\"A1345-Activity2-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Safety of the New Anti-VEGF Therapies: Findings From Treatment of nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 40px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\" target=\"_blank\" rel=\"noopener\"><u>Safety of the New Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\" aria-label=\"A1345-Activity5-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Switching to a New Anti-VEGF Agent for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\" target=\"_blank\" rel=\"noopener\"><u>Switching to a New Anti-VEGF Agent for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\" aria-label=\"A1345-Activity4-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Initiating New Anti-VEGF Therapies in Patients With nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\" target=\"_blank\" rel=\"noopener\"><u>Initiating New Anti-VEGF Therapies in Patients With nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_4 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\" aria-label=\"A1345-Activity1-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Translating the Latest Data for New Intravitreal Anti-VEGF Therapies to Treat nAMD in Clinical Practice\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\" target=\"_blank\" rel=\"noopener\"><u>Translating the Latest Data for New Intravitreal Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\" aria-label=\"A1345-Activity3-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Personalizing Treatment for nAMD Using New Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\" target=\"_blank\" rel=\"noopener\"><u>Personalizing Treatment for nAMD Using New Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><\/div><div class=\"w-separator hide_on_mobiles size_small\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row us_custom_308d0844 hide_on_default hide_on_laptops hide_on_mobiles height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_small\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"font-size: 24px; color: #332463;\">Featured Activities<\/div>\n<\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row namd-grid-4-2-1 via_grid cols_3 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:15px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\" aria-label=\"A1416-1-thumbnail-ver2\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\" target=\"_blank\" rel=\"noopener\"><u>Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-3\/\" aria-label=\"A1416-3-thumbnail\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Switching IVT Anti-VEGF Agents for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-3\/\" target=\"_blank\" rel=\"noopener\"><u>Switching IVT Anti-VEGF Agents for nAMD: So Many Options, How to Choose?<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-3\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-4\/\" aria-label=\"A1416-4-thumbnail\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 40px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-4\/\" target=\"_blank\" rel=\"noopener\"><u>When and How to Prioritize Injection Burden for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-4\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row namd-grid-4-2-1 via_grid cols_3 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:15px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-5\/\" aria-label=\"A1416-5-thumbnail\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Managing Retinal Fluid in Wet AMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-5\/\" target=\"_blank\" rel=\"noopener\"><u>The Human Side of nAMD: Balancing Vision, Life, and Treatment<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-5\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-2\/\" aria-label=\"A1416-2-thumbnail-ver2\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Getting Into the Details About Managing nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 40px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-2\/\" target=\"_blank\" rel=\"noopener\">Did You Know? Getting Into the Details About Managing nAMD<\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-2\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\" aria-label=\"A1345-Activity2-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Safety of the New Anti-VEGF Therapies: Findings From Treatment of nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 40px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\" target=\"_blank\" rel=\"noopener\"><u>Safety of the New Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_3 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:15px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\" aria-label=\"A1345-Activity5-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Switching to a New Anti-VEGF Agent for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 40px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\" target=\"_blank\" rel=\"noopener\"><u>Switching to a New Anti-VEGF Agent for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\" aria-label=\"A1345-Activity4-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Initiating New Anti-VEGF Therapies in Patients With nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\" target=\"_blank\" rel=\"noopener\"><u>Initiating New Anti-VEGF Therapies in Patients With nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 7px; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\" aria-label=\"A1345-Activity1-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Translating the Latest Data for New Intravitreal Anti-VEGF Therapies to Treat nAMD in Clinical Practice\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\" target=\"_blank\" rel=\"noopener\"><u>Translating the Latest Data for New Intravitreal Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 20px; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_3 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:15px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\" aria-label=\"A1345-Activity3-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Personalizing Treatment for nAMD Using New Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\" target=\"_blank\" rel=\"noopener\"><u>Personalizing Treatment for nAMD Using New Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><\/div><div class=\"w-separator hide_on_mobiles size_small\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row height_small\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:25px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"font-size: 24px; color: #332463;\">Archived<\/div>\n<\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_4 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" aria-label=\"A1280-Thumbnail01\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Extending Treatment Durability With Next-Generation nAMD Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" target=\"_blank\" rel=\"noopener\">Extending Treatment Durability With Next-Generation nAMD Therapies<\/a> <\/u><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" aria-label=\"A1280-Thumbnail02\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; line-height: 130%;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" target=\"_blank\" rel=\"noopener\">Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies<\/a><\/u><\/p>\n<p style=\"line-height: 120%;\">Infographic<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\" aria-label=\"A1280-Thumbnail03\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\" aria-label=\"A1280-Thumbnail04\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_4 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/extended-dosing-intervals-anti-vegf-therapies-for-namd\/\" aria-label=\"A1280-Thumbnail05\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail05-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Success With Extended Dosing Intervals of Anti-VEGF Therapies for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail05-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail05-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail05.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/extended-dosing-intervals-anti-vegf-therapies-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>Success With Extended Dosing Intervals of Anti-VEGF Therapies for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/extended-dosing-intervals-anti-vegf-therapies-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/long-acting-anti-vegf-therapies\/\" aria-label=\"A1280-Thumbnail06\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail06-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Strategies to Reduce Vision Loss in nAMD Using Long-Acting Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail06-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail06-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail06.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/long-acting-anti-vegf-therapies\/\" target=\"_blank\" rel=\"noopener\"><u>Strategies to Reduce Vision Loss in nAMD Using Long-Acting Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Patient Simulation<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/long-acting-anti-vegf-therapies\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"w-html\"><hr style=\"height:1px;border-width:0;color:#5d4c84;background-color:#5d4c84\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row us_custom_308d0844 hide_on_default hide_on_laptops hide_on_tablets hide_on_mobiles height_small width_full\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_middle type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"font-size: 24px; color: #332463;\">Archived<\/div>\n<\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" aria-label=\"A1280-Thumbnail01\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Extending Treatment Durability With Next-Generation nAMD Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" target=\"_blank\" rel=\"noopener\">Extending Treatment Durability With Next-Generation nAMD Therapies<\/a> <\/u><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" aria-label=\"A1280-Thumbnail02\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; line-height: 130%;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" target=\"_blank\" rel=\"noopener\">Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies<\/a><\/u><\/p>\n<p style=\"line-height: 120%;\">Infographic<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\" aria-label=\"A1280-Thumbnail03\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\" aria-label=\"A1280-Thumbnail04\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row hide_on_default hide_on_laptops hide_on_tablets hide_on_mobiles height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_2 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_custom\" style=\"height:15px\"><\/div><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" aria-label=\"A1280-Thumbnail01\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Extending Treatment Durability With Next-Generation nAMD Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" target=\"_blank\" rel=\"noopener\">Extending Treatment Durability With Next-Generation nAMD Therapies<\/a> <\/u><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_custom\" style=\"height:15px\"><\/div><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" aria-label=\"A1280-Thumbnail02\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" target=\"_blank\" rel=\"noopener\">Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies<\/a><\/u><\/p>\n<p style=\"line-height: 120%;\">Infographic<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"New Anti-VEGF Therapies for Neovascular Age-related Macular Degeneration This American Academy of Ophthalmology collection of activities provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD). Featured Activities Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice Webinar Credit...","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-943","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.eye-connect.org\/namd\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"nAMD - AdvAances in More Durable Treatments for the Management of nAMD\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"New Anti-VEGF Therapies For nAMD | AAO | Eye Connect\" \/>\n\t\t<meta property=\"og:description\" content=\"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.eye-connect.org\/namd\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2024-01-30T23:34:24+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-06-10T19:20:28+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"New Anti-VEGF Therapies For nAMD | AAO | Eye Connect\" \/>\n\t\t<meta name=\"twitter:description\" content=\"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#listItem\",\"name\":\"nAMD\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#listItem\",\"position\":2,\"name\":\"nAMD\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd#listItem\",\"name\":\"Home\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#organization\",\"name\":\"AAO\",\"description\":\"AdvAances in More Durable Treatments for the Management of nAMD\",\"url\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#webpage\",\"url\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/\",\"name\":\"New Anti-VEGF Therapies For nAMD | AAO | Eye Connect\",\"description\":\"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD.\",\"inLanguage\":\"en\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#breadcrumblist\"},\"datePublished\":\"2024-01-30T23:34:24-05:00\",\"dateModified\":\"2026-06-10T15:20:28-04:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#website\",\"url\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/\",\"name\":\"nAMD\",\"description\":\"AdvAances in More Durable Treatments for the Management of nAMD\",\"inLanguage\":\"en\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.eye-connect.org\\\/namd\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"New Anti-VEGF Therapies For nAMD | AAO | Eye Connect","description":"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD.","canonical_url":"https:\/\/www.eye-connect.org\/namd\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/www.eye-connect.org\/namd\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.eye-connect.org\/namd#listItem","position":1,"name":"Home","item":"https:\/\/www.eye-connect.org\/namd","nextItem":{"@type":"ListItem","@id":"https:\/\/www.eye-connect.org\/namd\/#listItem","name":"nAMD"}},{"@type":"ListItem","@id":"https:\/\/www.eye-connect.org\/namd\/#listItem","position":2,"name":"nAMD","previousItem":{"@type":"ListItem","@id":"https:\/\/www.eye-connect.org\/namd#listItem","name":"Home"}}]},{"@type":"Organization","@id":"https:\/\/www.eye-connect.org\/namd\/#organization","name":"AAO","description":"AdvAances in More Durable Treatments for the Management of nAMD","url":"https:\/\/www.eye-connect.org\/namd\/"},{"@type":"WebPage","@id":"https:\/\/www.eye-connect.org\/namd\/#webpage","url":"https:\/\/www.eye-connect.org\/namd\/","name":"New Anti-VEGF Therapies For nAMD | AAO | Eye Connect","description":"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD.","inLanguage":"en","isPartOf":{"@id":"https:\/\/www.eye-connect.org\/namd\/#website"},"breadcrumb":{"@id":"https:\/\/www.eye-connect.org\/namd\/#breadcrumblist"},"datePublished":"2024-01-30T23:34:24-05:00","dateModified":"2026-06-10T15:20:28-04:00"},{"@type":"WebSite","@id":"https:\/\/www.eye-connect.org\/namd\/#website","url":"https:\/\/www.eye-connect.org\/namd\/","name":"nAMD","description":"AdvAances in More Durable Treatments for the Management of nAMD","inLanguage":"en","publisher":{"@id":"https:\/\/www.eye-connect.org\/namd\/#organization"}}]},"og:locale":"en_US","og:site_name":"nAMD - AdvAances in More Durable Treatments for the Management of nAMD","og:type":"article","og:title":"New Anti-VEGF Therapies For nAMD | AAO | Eye Connect","og:description":"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD.","og:url":"https:\/\/www.eye-connect.org\/namd\/","article:published_time":"2024-01-30T23:34:24+00:00","article:modified_time":"2026-06-10T19:20:28+00:00","twitter:card":"summary_large_image","twitter:title":"New Anti-VEGF Therapies For nAMD | AAO | Eye Connect","twitter:description":"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD."},"aioseo_meta_data":{"post_id":"943","title":"New Anti-VEGF Therapies For nAMD | AAO | Eye Connect","description":"This AAO initiative provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-VEGF agents for nAMD.","keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":true,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2024-01-31 15:18:25","updated":"2026-06-10 20:15:06","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.eye-connect.org\/namd\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tnAMD\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.eye-connect.org\/namd"},{"label":"nAMD","link":"https:\/\/www.eye-connect.org\/namd\/"}],"_links":{"self":[{"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/pages\/943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/comments?post=943"}],"version-history":[{"count":207,"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/pages\/943\/revisions"}],"predecessor-version":[{"id":2122,"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/pages\/943\/revisions\/2122"}],"wp:attachment":[{"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/media?parent=943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}